دورية أكاديمية
Onvansertib in Combination with FOLFIRI and Bevacizumab in Second-Line Treatment of KRAS-Mutant Metastatic Colorectal Cancer: A Phase Ib Clinical Study.
| العنوان: | Onvansertib in Combination with FOLFIRI and Bevacizumab in Second-Line Treatment of KRAS-Mutant Metastatic Colorectal Cancer: A Phase Ib Clinical Study. |
|---|---|
| المؤلفون: | Ahn, Daniel H, Barzi, Afsaneh, Ridinger, Maya, Samuëlsz, Errin, Subramanian, Ramanand A, Croucher, Peter J P, Smeal, Tod, Kabbinavar, Fairooz F, Lenz, Heinz-Josef |
| المصدر: | Clin Cancer Res ; ISSN:1557-3265 ; Volume:30 ; Issue:10 |
| بيانات النشر: | Silverchair Information Systems |
| سنة النشر: | 2024 |
| المجموعة: | PubMed Central (PMC) |
| الوصف: | Onvansertib is a highly specific inhibitor of polo-like kinase 1 (PLK1), with demonstrated safety in solid tumors. We evaluated, preclinically and clinically, the potential of onvansertib in combination with chemotherapy as a therapeutic option for KRAS-mutant colorectal cancer. |
| نوع الوثيقة: | article in journal/newspaper |
| اللغة: | English |
| العلاقة: | https://doi.org/10.1158/1078-0432.CCR-23-3053Test; https://pubmed.ncbi.nlm.nih.gov/38231047Test; https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11094418Test/ |
| DOI: | 10.1158/1078-0432.CCR-23-3053 |
| الإتاحة: | https://doi.org/10.1158/1078-0432.CCR-23-3053Test https://pubmed.ncbi.nlm.nih.gov/38231047Test https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11094418Test/ |
| حقوق: | ©2024 The Authors; Published by the American Association for Cancer Research. |
| رقم الانضمام: | edsbas.B4ADC899 |
| قاعدة البيانات: | BASE |
| DOI: | 10.1158/1078-0432.CCR-23-3053 |
|---|